Pharmafile Logo
Pharmafocus logo
Advanced Search

darzalex

Showing 15 posts of 27 posts found.

darzalex-product-shot---100mg-vial-2-hr

Genmab’s Darzalex secures CHMP recommendation in Europe for front-line multiple myeloma

December 13, 2019
Medical Communications, Sales and Marketing CHMP, Genmab, darzalex, pharma

The Committee for Medicinal Products for Human Use (CHMP), an advisory panel for the European Medicines Agency, has given its …

News
janssen_latest_logo_on_sign

Janssen’s Darzalex combo shows strong overall survival benefit at ASH 2019

December 10, 2019
Manufacturing and Production, Research and Development ASH 19, Janssen, darzalex, pharma

Janssen has unveiled new Phase 3 data on the efficacy of Darzalex (daratumumab) when combined with bortezomib, melphalan and prednisone …

News
darzalex-product-shot---100mg-vial-2-hr

European Commission approves Genmab’s Darzalex combo in newly diagnosed multiple myeloma

November 20, 2019
Research and Development, Sales and Marketing Europe, Genmab, darzalex, pharma

Genmab’s Darzalex (daratumumab) has secured approval from the European Commission and is now authorised in Europe for the treatment of …

News
darzalex-product-shot---100mg-vial-2-hr

FDA approves Genmab’s Darzalex combo in newly diagnosed multiple myeloma

September 27, 2019
Medical Communications, Sales and Marketing FDA, Genmab, darzalex, pharma

Genmab’s CD38 inhibitor Darzalex (daratumumab) has been awarded marketing authorisation from the FDA in combination with bortezomib, thalidomide and dexamethasone …

News
amgen_flag

Amgen’s Kyprolis + Darzalex combo shows progression-free survival benefit in multiple myeloma

September 16, 2019
Research and Development, Sales and Marketing Amgen, Kyrpolis, darzalex, multiple myeloma, pharma

Amgen has revealed new Phase 3 data for the combination of Kyprolis (carfilzomib) and Darzalex (daratumumab) in addition to the …

News
janssen_latest_logo_on_sign

Janssen’s Darzalex combo approved by FDA in transplant-ineligible multiple myeloma patients

June 28, 2019
Medical Communications, Sales and Marketing Janssen, darzalex, mutiple myeloma, pharma

Janssen’s Darzalex (daratumumab) has secured FDA approval in combination with lenalidomide and dexamethasone for the treatment of newly diagnosed multiple …

News
shutterstock_159488225

Darzalex combo makes strong Phase 3 showing in multiple myeloma

June 4, 2019
Manufacturing and Production, Research and Development ASCO 2019, Cancer, Janssen, darzalex, multiple myeloma, pharma

Janssen joined its contemporaries at the 55th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago in the release …

News
janssen_latest_logo_on_sign

Janssen presents strong Phase 3 showing for Darzalex in multiple myeloma subgroup

May 30, 2019
Research and Development Janssen, darzalex, pharma

Janssen has lifted the curtain on new Phase 3 data for Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (Rd), …

News
janssen_latest_logo_on_sign

NICE recommends Janssen’s Darzalex myeloma combo

March 12, 2019
Manufacturing and Production Janssen, NICE, Velcade, darzalex, myeloma

Britain’s cost effectiveness body NICE have recommended Janssen Pharmaceutical’s Darzalex in combination with Velcade and dexamethasone (DVd), for use within …

News
janssen_latest_logo_on_sign_closer

Darzalex “significantly reduces” disease progression and death in multiple myeloma at ASH 2018

December 5, 2018
Research and Development ASH 2018, Janssen, darzalex, multiple myeloma, pharma

Janssen has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to unveil new Phase 3 …

News
janssen_latest_logo_on_sign

Europe approves Janssen’s Darzalex in frontline multiple myeloma

September 4, 2018
Manufacturing and Production, Research and Development, Sales and Marketing EU, Europe, J&J, JJ, Janssen, darzalex, multiple myeloma, pharma

Janssen has revealed that its CD38-targeting biologic drug Darzalex (daratumumab) has received approval from the European Commission, authorising its use …

News
jj

J&J terminates PD-(L)1 combo studies of cancer therapy Darzalex

May 29, 2018
Manufacturing and Production, Research and Development Cancer, Genmab, J&J, JJ, Johnson & Johnson, Roche, darzalex, multiple myeloma, tecentriq

Johnson & Johnson is to terminate its studies investigating Genmab’s CD38-targeting, human IgG1κ monoclonal antibody Darzalex (daratumumab) in combination with …

News

Genmab and Janssen’s Darzalex combo scores FDA approval in multiple myeloma

May 8, 2018
Manufacturing and Production, Sales and Marketing FDA, Genmab, Janssen, US, darzalex, multiple myeloma, pharma

Genmab and Janssen have revealed that their combination of Darzalex (daratumumab) with bortezomib (Velcade), melphalan, and prednisone (VMP) has received …

News
darzalex

NICE meets Janssen halfway over Darzalex

January 18, 2018
Medical Communications, Sales and Marketing J&J, JJ, Janssen, biotech, darzalex, drugs, pharma, pharmaceutical

NICE rejected Janssen’s Darzalex (Daratumumab) back in March last year, concluding that it wasn’t able to accurately determine the efficacy …

News

J&J’s Darzalex cuts risk of disease progression and death by 50%, new study shows

December 13, 2017
Research and Development Genmab, J&J, JJ, Janssen, Johnson & Johnson, darzalex, multiple myeloma, pharma

Johnson and Johnson has revealed data which demonstrates that Darzalex (daratumumab), when combined with a regimen of bortezomib, melphalan and …

News

Latest content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024